Aarkstore - Ophthalmic Drugs; Data, Analysis and Forecasts to 2024

Aarkstore - Ophthalmic Drugs; Data, Analysis and Forecasts to 2024

Browse Full Report @

http://www.aarkstore.com/healthcare/67271/ophthalmic-drugs-data-analysis-and-forecasts

Published: Mar 2014 | 151 Pages

PDF: € 1799| Site License: € 3599 | Enterprise Wide Licence: € 8499

Summary

Which ophthalmic drugs lead the market in 2013? Will the same drugs be as successful in 2018? How will this landscape change across the next 10 years? Which trial drugs are likely to make an impact? Only one report will tell you the answers. Simply by ordering and reading GMR Data’s new ‘Ophthalmic Drugs; Data, Analysis and Forecasts to 2024’ report, you can stay ahead of your competition. It really is that simple.

GMR Data forecasts that the global ophthalmic drugs market will reach $9.7bn by 2024. The US market growth will be slow compared to other markets predominantly due to major drug patent expiry and generic erosion. For example;

• Xalabrands from Pfizer used for treatment of Glaucoma expired in the US in March 2011.

• Azopt by Alcon used for treatment of Glaucoma expired in the US in October 2012.

• Lumigan by Allergan used for treatment of Glaucoma expired in the US in 2013.

• Restasis from Allergan used for treatment of Dry eye will expire in the US in May 2014.

• Travatan by Alcon used for treatment of Glaucoma will expire in the US in 2014.

• Combigan by Allergan used for treatment of Glaucoma will expire in the US in 2022.

• Lucentis from Novartis used for treatment of Retinal Disorder will expire in the US in June 2020.

Restasis by Allergan is the market-leading drug in the ophthalmic market with sales of $1bn across 2013. Will it be able to see off the competition for the next 5 years? The next 10 years? This report tells you. With an assessment of the leading markets, such as the US, and EU, GMR Data examine how Germany and France are the largest EU markets and what % of the global market they make up. Which other countries contribute most?...